French health insurance databases: What interest for medical research?

Revue de Medecine Interne

Volumn 36, Issue 6, 2015, Pages 411-417

  Moulis, G ^a,b,c   Lapeyre Mestre, M ^b,c,d   Palmaro, A ^b,c   Pugnet, G ^a,b,c   Montastruc, J L ^b,c,d,e   Sailler, L ^a,b,c  

^a CHU PURPAN   (France)

^b Faculté de Médecine Centre Hospitalo universitaire   (France)

^c INSERM   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

France; Health insurance; Medico administrative databases; Syst me national d'information inter r gime de l'assurance maladie; chantillon g n raliste des b n ficiaires

Indexed keywords

ACCESS TO INFORMATION; DATA BASE; DEMOGRAPHY; DIGITAL COMPUTER; DISEASE DURATION; DRUG DISPENSING; DRUG DISTRIBUTION; ELECTRONIC MEDICAL RECORD; FRENCH HEALTH INSURANCE DATABASE; FRENCHMAN; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; LAW; MEDICAL LEAVE; MEDICAL RESEARCH; NATIONAL HEALTH INSURANCE; OCCUPATIONAL DISEASE; RANDOM SAMPLE; REIMBURSEMENT; SHORT SURVEY; FACTUAL DATABASE; FRANCE;

BIOMEDICAL RESEARCH; DATABASES, FACTUAL; FRANCE; HUMANS; INSURANCE, HEALTH;

EID: 84930379677     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.11.009     Document Type: Short Survey

References (37)

1. Haut Conseil de la Santé Publique Pour une meilleure utilisation des bases de données administratives et médico-administratives nationales pour la santé publique et la recherche 2012, [Accessed 01 July 2014]. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=258.
2. Bras P.-L., Loth A. Rapport sur la gouvernance et l'utilisation des données de santé 2013, [Accessed 01 July 2014]. http://www.social-sante.gouv.fr/IMG/pdf/Rapport_donnees_de_sante_2013.pdf.
3. Bases de données utilisables. Portail Épidémiologie-France. Available at: . [Accessed 01 July 2014]. https://epidemiologie-france.aviesan.fr/.
4. Tuppin P., de Roquefeuil L., Weill A., Ricordeau P., Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010, 58:286-290.
5. De Roquefueil L., Studer A., Neumann A., Merlière Y. L'échantillon généraliste des bénéficiaires: rerpésentativité, portée et limites. Prat Organisation Soins 2009, 40:213-223.
6. o98-1194 du 23 décembre 1998 de financement de la sécurité sociale pour 1999. Journal Officiel de La République Française 1998, 300:19646.
7. Arrêté du 19 juillet 2013 relatif à la mise en œuvre du Système national d'information interrégimes de l'assurance maladie. Journal Officiel de La République Française 2013, 0187:13791.
8. World Health Organization International Classification of Diseases 2014, [Accessed 01 July 2014]. http://www.who.int/classifications/icd/en/.
9. o2004-810 du 13 aoÛt 2004 relative à l'assurance maladie. Journal Officiel de La République Française 2004, 190:14598.
10. Institut des Données de Santé Rapport au Parlement 2013, [Accessed 01 July 2014]. http://www.institut-des-donnees-de-sante.fr/telechargements/RA-IDS-2013bdf.pdf.
11. Riou C., Fresson J., Serre J., Avillach P., Leveneut L., Quantin C. Guide de bonne pratiques permettant d'assurer la confidentialité des données de santé recueilies en milieu hospitalier lors de leur réutilisation à des fins de traitement statistique 2013, [Accessed 01 July 2014]. http://emois.org/images/EMOIS2014/soumission_resp.pdf.
12. Arnaud L., Fagot J.-P., Paita M., Fagot-Campagna A., Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev 2014, 10.1016/j.autrev.2014.08.034.
13. Moulis G., Palmaro A., Montastruc J.-L., Godeau B., Lapeyre-Mestre M., Sailler L. Epidemiology of incident immune thrombocytopenia in France: a nationwide population-based study. Blood 2014, 124:3308-3315.
14. Quantin C., Benzenine E., Hägi M., Auverlot B., Abrahamowicz M., Cottenet J., et al. Estimation of national colorectal-cancer incidence using claims databases. J Cancer Epidemiol 2012, 2012:298369.
15. Bannay A., Chaignot C., Blotière P.-O., Weill A., Ricordeau P., Alla F., et al. Score de Charlson à partir des données du Sniiram chaînées au PMSI: faisabilité et valeur pronostique sur la mortalité à un an. Rev Epidemiol Sante Publique 2013, 61:S9.
16. Tuppin P., Cuerq A., de Peretti C., Fagot-Campagna A., Danchin N., Juillière Y., et al. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis 2013, 106:570-585.
17. Rey G., Jougla E., Fouillet A., Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 2009, 9:33.
18. Tuppin P., Samson S., Weill A., Ricordeau P., Allemand H. Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009. Vaccine 2011, 29:4632-4637.
19. Fagot J.-P., Boutrelle A., Ricordeau P., Weill A., Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011, 29:3610-3616.
20. Moulis G., Lapeyre-Mestre M., Adoue D., Sailler L. L'exposition aux vaccins recommandés est faible chez les patients non splénectomisés atteints de thrombopénie immunologique primaire et exposés au rituximab. Résultats de l'étude FAITH (French Adult Immune Thrombocytopenia: a pharmacoepidemiological study). Rev Med Interne 2014, 35:A78-A79.
21. Haute Autorité de santé Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins 2009, [Accessed 01 July 2014]. http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-12/ald_2_pnds_pti_imune_enft_adulte_web.pdf.
22. Fautrel B., Joubert J.-M., Cukierman G., Laurendeau C., Gourmelen J., Fagnani F. Rheumatoid arthritis (RA), comorbidities and biological agents uptake in France: analysis of a national claims database. Ann Rheum Dis 2013, 72:337.
23. Bezin J., Pariente A., Lassalle R., Dureau-Pournin C., Abouelfath A., Robinson P., et al. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. Eur J Clin Pharmacol 2014, 70:429-436.
24. Dupouy J., Fournier J.-P., Jouanjus É., Palmaro A., Poutrain J.-C., Oustric S., et al. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns: a cohort study. Eur Neuropsychopharmacol 2014, 24:192-199.
25. Gallini A., Andrieu S., Donohue J.M., Oumouhou N., Lapeyre-Mestre M., Gardette V. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol 2014, 24:95-104.
26. Pariente A., Pinet M., Moride Y., Merlière Y., Moore N., Fourrier-Réglat A. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf 2010, 19:680-686.
27. Neumann A., Maura G., Weill A., Ricordeau P., Alla F., Allemand H. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf 2014, 23:240-250.
28. Weill A., Païta M., Tuppin P., Fagot J.-P., Neumann A., Simon D., et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010, 19:1256-1262.
29. Neumann A., Weill A., Ricordeau P., Fagot J.P., Alla F., Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
30. Blin P., Lassalle R., Dureau-Pournin C., Ambrosino B., Bernard M.A., Abouelfath A., et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012, 55:644-653.
31. Blotière P.-O., Weill A., Ricordeau P., Alla F., Allemand H. Perforations and haemorrhages after colonoscopy in 2010: a study based on comprehensive French health insurance data (SNIIRAM). Clin Res Hepatol Gastroenterol 2014, 38:112-117.
32. Dixon W.G., Abrahamowicz M., Beauchamp M.-E., Ray D.W., Bernatsky S., Suissa S., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71:1128-1133.
33. Dixon W.G., Kezouh A., Bernatsky S., Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011, 70:956-960.
34. Moulis G., Sailler L., Adoue D., Lapeyre-Mestre M. Pharmacoepidemiology of immune thrombocytopenia: protocols of FAITH and CARMEN studies. Therapie 2014, 69:437-448.
35. World Health Organization ATC/DDD Index 2014, [Accessed 01 July 2014]. http://www.whocc.no/atc_ddd_index/.
36. Pottegård A., Hallas J. Assigning exposure duration to single prescriptions by use of the waiting time distribution. Pharmacoepidemiol Drug Saf 2013, 22:803-809.
37. Sylvestre M.-P., Abrahamowicz M. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med 2009, 28:3437-3453.